hVIVO plc (LON:HVO - Get Free Report) dropped 7.6% during trading on Wednesday . The stock traded as low as GBX 22 ($0.28) and last traded at GBX 22 ($0.28). Approximately 2,996,261 shares traded hands during trading, a decline of 15% from the average daily volume of 3,527,909 shares. The stock had previously closed at GBX 23.80 ($0.30).
hVIVO Price Performance
The firm's 50 day moving average price is GBX 27.95 and its two-hundred day moving average price is GBX 28.08. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock has a market cap of £150.36 million, a PE ratio of 724.17 and a beta of 0.97.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
